Contineum Therapeutics, Inc. (CTNM) Financials
A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Oct 10, 2026; every other figure is from the SEC filings on this page. Not financial advice.
Newest figures come from the 10-Q for Q2 FY2026, filed Jul 30, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the CTNM SEC filings page.
This page shows Contineum Therapeutics, Inc. (CTNM) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 3 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Contineum is funding a research-heavy business through outside capital, with losses and cash use rising as equity expands.
Operating cash consumption worsened from$32.8M in FY2024 to$55.3M in FY2025. R&D also increased over that span, while net loss tracked operating cash flow closely, linking the deterioration to core development spending rather than a large non-cash gap.
Assets reached
Cash use is operational rather than capital-intensive: free cash flow was
Financial Health Signals
Contineum Therapeutics, Inc. does not currently provide enough eligible data for a peer-relative financial health score, so none is published. The signals and metrics below are current.
Contineum Therapeutics, Inc. passes 2 of 5 computable financial strength tests (4 of the nine could not be computed from available data). 1 of 4 profitability signals pass, all 1 leverage/liquidity signals pass.
Contineum Therapeutics, Inc. reported a net loss of $60.0M while operations used $55.3M of cash. With neither figure positive, the ratio between the two carries no quality signal.
Key Financial Metrics
Earnings & Revenue
Contineum Therapeutics, Inc.'s EBITDA was -$17.3M in Q2 2026, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 3.0% from the same quarter a year earlier. Against the prior quarter it is down 2.8%.
Contineum Therapeutics, Inc. reported -$15.2M in net income in Q2 2026. This represents an increase of 5.5% from the same quarter a year earlier. Against the prior quarter it is down 4.8%.
Contineum Therapeutics, Inc. earned -$0.40 per diluted share (EPS) in Q2 2026. This represents an increase of 35.5% from the same quarter a year earlier. Against the prior quarter it is down 2.6%.
Not reported for Q2 2026.
Cash & Balance Sheet
Contineum Therapeutics, Inc. recorded an outflow of $11.5M in free cash flow in Q2 2026, representing a cash shortfall after capex. This represents an increase of 26.7% from the same quarter a year earlier. Against the prior quarter it is up 30.6%.
Contineum Therapeutics, Inc. held $14.7M in cash as of Q2 2026; long-term debt is not reported for that period.
Not reported for Q2 2026.
Margins & Returns
Contineum Therapeutics, Inc.'s ROE was -6.3% in Q2 2026, measuring profit generated per dollar of shareholder equity. This is up 3.0 percentage points from the same quarter a year earlier. Against the prior quarter it is down 0.5 percentage points.
Not reported for Q2 2026.
Not reported for Q2 2026.
Not reported for Q2 2026.
Capital Allocation
Contineum Therapeutics, Inc. invested $12.7M in research and development in Q2 2026. This represents a decrease of 9.7% from the same quarter a year earlier. Against the prior quarter it is up 9.0%.
Contineum Therapeutics, Inc. invested $6K in capex in Q2 2026, funding long-term assets and infrastructure. This represents a decrease of 86.4% from the same quarter a year earlier. Against the prior quarter it is down 98.1%.
Not reported for Q2 2026.
CTNM Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Revenue | N/A | N/A | N/A | N/A | N/A | N/A | N/A | $0 |
| R&D Expenses | $12.7M-9.7% | $11.6M-15.1% | N/A | $11.0M+13.0% | $14.1M+78.0% | $13.7M+76.3% | N/A | $9.7M+49.7% |
| SG&A Expenses | $4.7M+23.1% | $5.3M+19.5% | N/A | $3.9M+21.4% | $3.8M+26.2% | $4.4M+104.4% | N/A | $3.2M+106.8% |
| Operating Income | -$17.4M+2.6% | -$16.9M+6.7% | N/A | -$14.9M-15.1% | -$17.9M-63.6% | -$18.1M-82.4% | N/A | -$13.0M-60.8% |
| EBITDA | -$17.3M+3.0% | -$16.8M+6.7% | N/A | -$14.9M-15.0% | -$17.8M-63.8% | -$18.0M-82.7% | N/A | -$12.9M-60.9% |
| Interest Expense | N/A | N/A | N/A | N/A | N/A | N/A | N/A | $0 |
| Income Tax | N/A | N/A | N/A | N/A | N/A | N/A | N/A | $0+100.0% |
| Net Income | -$15.2M+5.5% | -$14.5M+9.6% | N/A | -$12.8M-24.6% | -$16.0M-78.0% | -$16.0M-90.0% | N/A | -$10.3M-64.2% |
| EPS (Basic) | -$0.40+35.5% | -$0.39+37.1% | -$0.49+14.0% | -$0.45-12.5% | -$0.62-59.0% | -$0.62+82.5% | -$0.57-7.5% | -$0.40+85.1% |
| EPS (Diluted) | -$0.40+35.5% | -$0.39+37.1% | N/A | N/A | -$0.62-59.0% | -$0.62 | -$0.57 | -$0.40 |
| Diluted Shares (Avg) | 37M+44.7% | 37M+44.3% | N/A | N/A | 26M+10.9% | 26M | N/A | 26M |
Not reported in any period shown, so not listed: Cost of Revenue, Gross Profit.
CTNM Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $250.4M+36.9% | $261.3M+31.8% | $276.6M+30.0% | $190.8M-11.7% | $182.9M-17.4% | $198.3M+60.5% | $212.8M+63.2% | $216.0M |
| Current Assets | $242.6M+37.2% | $253.0M+31.7% | $267.9M+29.8% | $184.9M-14.0% | $176.8M-19.7% | $192.1M+60.5% | $206.4M+61.6% | $215.1M |
| Cash & Equivalents | $14.7M-29.2% | $20.2M-10.3% | $75.6M+244.5% | $42.6M+4.3% | $20.8M-73.1% | $22.5M+38.2% | $21.9M+41.3% | $40.9M |
| Short-Term Investments | $221.8M+43.4% | $226.2M+34.4% | $187.3M+2.4% | $139.8M-19.2% | $154.7M+9.4% | $168.2M+65.5% | $182.8M+66.7% | $173.0M |
| Long-Term Investments | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Total Liabilities | $10.7M-6.9% | $11.3M-16.2% | $15.7M+5.9% | $10.4M+78.7% | $11.5M+198.5% | $13.5M-93.2% | $14.8M-92.5% | $5.8M |
| Current Liabilities | $6.5M-9.5% | $6.7M-25.6% | $9.7M-2.3% | $6.4M+9.6% | $7.2M+92.9% | $8.9M+43.6% | $10.0M+81.9% | $5.8M |
| Non-Current Liabilities | $4.2M-2.4% | $4.7M+2.3% | $5.9M+22.9% | $4.0M | $4.3M+3691.2% | $4.5M-97.6% | $4.8M-97.5% | $0 |
| Total Equity | $239.7M+39.8% | $250.0M+35.3% | $261.0M+31.8% | $180.5M-14.2% | $171.4M-21.2% | $184.8M+344.3% | $198.1M+391.5% | $210.2M+443.8% |
| Retained Earnings | -$207.0M-38.5% | -$191.8M-43.8% | -$177.4M-51.1% | -$162.2M-57.7% | -$149.4M-61.4% | -$133.4M-59.6% | -$117.4M-56.2% | -$102.8M |
Not reported in any period shown, so not listed: Inventory, Accounts Receivable, Goodwill, Long-Term Debt.
CTNM Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$11.5M+26.6% | -$16.3M-12.9% | -$13.0M-27.8% | -$12.2M-97.7% | -$15.7M-84.3% | -$14.4M-80.7% | -$10.2M+4.7% | -$6.2M-14.7% |
| Depreciation & Amortization | $134K+69.6% | $83K+6.4% | $85K+13.3% | $81K+30.6% | $79K+31.7% | $78K+27.9% | $75K+102.7% | $62K+44.2% |
| Stock-Based Compensation | $3.8M+58.8% | $3.8M+48.8% | N/A | $2.6M+12.1% | $2.4M | $2.6M+234.5% | N/A | $2.3M |
| Capital Expenditures | $6K-86.4% | $312K+563.8% | $42K-74.7% | $98K+19.5% | $44K-63.0% | $47K-68.0% | $166K-46.3% | $82K+272.7% |
| Free Cash Flow | -$11.5M+26.7% | -$16.6M-14.7% | -$13.1M-26.2% | -$12.3M-96.7% | -$15.7M-82.2% | -$14.5M-78.0% | -$10.4M+5.9% | -$6.3M-15.8% |
| Investing Cash Flow | $4.9M-65.0% | -$39.3M-363.5% | -$47.5M-405.5% | $14.9M+149.5% | $13.9M+135.7% | $14.9M+70.8% | -$9.4M-204.0% | -$30.2M+23.6% |
| Financing Cash Flow | $1.2M+1218.7% | $129K+437.5% | $93.5M+14458.4% | $19.1M+146861.5% | $91K-99.9% | $24K+233.3% | $642K+300.0% | $13K-99.9% |
Not reported in any period shown, so not listed: Dividends Paid, Share Buybacks.
CTNM Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Return on Equity | -6.3%+3.0pp | -5.8%+2.9pp | N/A | -7.1%-2.2pp | -9.4%-5.2pp | -8.6% | N/A | -4.9% |
| Return on Assets | -6.0%+2.7pp | -5.5%+2.5pp | N/A | -6.7%-2.0pp | -8.8%-4.7pp | -8.1%-1.3pp | N/A | -4.8% |
| Current Ratio | 37.17+12.7x | 38.00+16.5x | 27.50+6.8x | 29.07-8.0x | 24.51-34.4x | 21.47+2.3x | 20.69-2.6x | 37.06 |
| Debt-to-Equity | 0.040.0x | 0.050.0x | 0.060.0x | 0.060.0x | 0.070.0x | 0.07 | 0.07 | 0.03 |
| Asset Turnover | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 0.00 |
Not reported in any period shown, so not listed: Gross Margin, Operating Margin, Net Margin, FCF Margin.
Similar Companies
Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.
| Company | Fiscal year | Revenue | Net income | Net margin | Market cap | Health score |
|---|---|---|---|---|---|---|
| Contineum Therapeutics, Inc. CTNM | FY2025 | N/A | -$60.0M | N/A | $503.4M | — |
| Tectonic Therapeutic, Inc. TECX | FY2025 | N/A | N/A | N/A | $456.1M | — |
| Aldeyra Therapeutics, Inc. ALDX | FY2025 | N/A | -$33.8M | N/A | $55.3M | — |
| Larimar Therapeutics, Inc. LRMR | FY2025 | N/A | -$165.7M | N/A | $277.4M | — |
| Immuneering Corporation IMRX | FY2025 | N/A | -$56.0M | N/A | $254.9M | — |
| Design Therapeutics, Inc. DSGN | FY2025 | $0 | -$69.8M | N/A | $729.1M | — |
Where Contineum Therapeutics, Inc. Ranks
Frequently Asked Questions
Is Contineum Therapeutics, Inc. profitable?
No, Contineum Therapeutics, Inc. (CTNM) reported a net income of -$60.0M in fiscal year 2025.
What is Contineum Therapeutics, Inc.'s EBITDA?
Contineum Therapeutics, Inc. (CTNM) had EBITDA of -$67.7M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
What is Contineum Therapeutics, Inc.'s return on equity (ROE)?
Contineum Therapeutics, Inc. (CTNM) has a return on equity of -23.0% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is Contineum Therapeutics, Inc.'s free cash flow?
Contineum Therapeutics, Inc. (CTNM) recorded an outflow of $55.5M in free cash flow during fiscal year 2025. This represents a -66.5% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Contineum Therapeutics, Inc.'s operating cash flow?
Contineum Therapeutics, Inc. (CTNM) recorded an outflow of $55.3M in operating cash flow during fiscal year 2025, representing cash used by core business activities.
What are Contineum Therapeutics, Inc.'s total assets?
Contineum Therapeutics, Inc. (CTNM) had $276.6M in total assets as of fiscal year 2025, including both current and long-term assets.
What are Contineum Therapeutics, Inc.'s capital expenditures?
Contineum Therapeutics, Inc. (CTNM) invested $231K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
How much does Contineum Therapeutics, Inc. spend on research and development?
Contineum Therapeutics, Inc. (CTNM) invested $51.5M in research and development during fiscal year 2025.
What is Contineum Therapeutics, Inc.'s current ratio?
Contineum Therapeutics, Inc. (CTNM) had a current ratio of 27.50 as of fiscal year 2025, which is generally considered healthy.
What is Contineum Therapeutics, Inc.'s debt-to-equity ratio?
Contineum Therapeutics, Inc. (CTNM) had a debt-to-equity ratio of 0.06 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Contineum Therapeutics, Inc.'s return on assets (ROA)?
Contineum Therapeutics, Inc. (CTNM) had a return on assets of -21.7% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is Contineum Therapeutics, Inc.'s P/E ratio?
Contineum Therapeutics, Inc. (CTNM) has no price-to-earnings ratio at the moment: net loss, so no earnings multiple (FY2025). The market capitalization is $503.4M as of Oct 10, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
What is Contineum Therapeutics, Inc.'s price-to-sales ratio?
Contineum Therapeutics, Inc. (CTNM) has no price-to-sales ratio at the moment: no revenue reported. The market capitalization is $503.4M as of Oct 10, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
How does Contineum Therapeutics, Inc.'s liquidity compare with its operating cash outflow?
At the end of fiscal year 2025, Contineum Therapeutics, Inc. (CTNM) held $262.9M in cash, cash equivalents and investments, and reported an operating cash outflow of $55.3M over that year. Dividing the one by the other, the reported balance equals about 57 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.
What is Contineum Therapeutics, Inc.'s Piotroski F-Score?
Contineum Therapeutics, Inc. (CTNM) has a Piotroski F-Score of 2 out of 5 computable signals; 4 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Contineum Therapeutics, Inc.'s earnings high quality?
Contineum Therapeutics, Inc. (CTNM) reported a net loss of $60.0M while operations used $55.3M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.